/주식/IDYA
IDYA

IDYA

USD

IDEAYA Biosciences Inc. Common Stock

$30.240+0.800 (2.717%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$29.440

고가

$30.450

저가

$28.840

거래량

0.19M

기업 기본 정보

시가총액

2.7B

산업

생명공학

국가

United States

거래 통계

평균 거래량

1.21M

거래소

NMS

통화

USD

52주 범위

저가 $13.45현재가 $30.240고가 $33.64

관련 뉴스

PR Newswire

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results...

더 보기
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

더 보기
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

더 보기
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
Analyst Upgrades

JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $79

JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences with a Overweight and raises the price target from $74 to $79.

더 보기
JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $79
Analyst Upgrades

Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $30

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences with a Neutral and raises the price target from $27 to $30.

더 보기
Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $30
Analyst Upgrades

RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $41

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences with a Outperform and raises the price target from $38 to $41.

Analyst Upgrades

BTIG Reiterates Buy on IDEAYA Biosciences, Maintains $62 Price Target

BTIG analyst Justin Zelin reiterates IDEAYA Biosciences with a Buy and maintains $62 price target.